IGF1R and cancer: Several strategies of IGF-1R inhibition, such as using monoclonalantibody, antisense oligonucleotides, and small molecule kinase inhibitors directed against IGF-1R, have been developed for cancer therapy and have shown antitumor efficacy [28–30], but their clinical responses remain to be seen.